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Objectives: Pericardial effusion occurs frequently after orthotopic heart transplan-
tation, but the causes of this complication have not been well described. This study
was designed to identify factors predisposing toward the development of significant
postoperative pericardial effusions in a large, single-institution population of ortho-
topic heart transplant recipients.
Methods: A retrospective review of more than 90 preoperative, intraoperative, and
postoperative variables was conducted for 241 patients undergoing orthotopic heart
transplantation from September 1988 to December 1999. Patients who had signif-
icant postoperative pericardial effusions develop were identified from postoperative
echocardiograms by standard criteria. Factors associated with the development of
significant pericardial effusions were determined by multivariate logistic regression
analysis.
Results: Echocardiographic data were available for 203 of 241 transplant recipients.
Forty-two patients (21%) had significant effusions develop. According to multivar-
iate analysis, pericardial effusions were less likely to occur in recipients with a
history of previous cardiac surgery (odds ratio 0.13, 95% confidence interval
0.05-0.36, P  .0001) and with greater weight (odds ratio 0.96, 95% confidence
interval 0.94-0.99, P  .0048). Pericardial effusions were more likely to occur in
patients who had received aminocaproic acid during the operation (odds ratio 5.92,
95% confidence interval 2.23-15.72, P  .0008). Patient survival and hospital
length of stay did not differ between patients with and without postoperative
pericardial effusions.
Conclusions: Postoperative pericardial effusions develop in approximately 20% of
patients undergoing orthotopic cardiac transplantation. On the basis of the risk
factors identified in this study, prevention may prove difficult, although avoidance
of the intraoperative use of aminocaproic acid may be helpful.
Pericardial effusion occurs frequently after all forms of cardiac sur-gery,1 and its appearance has been associated with postoperativebleeding,2 postpericardiotomy syndrome,3 and postoperative antico-agulation.4 Effusions are frequently detected after orthotopic cardiactransplantation, but the factors associated with the development ofpericardial effusion in this setting may differ from those in other
situations. Moderate or large pericardial effusions have been reported to occur more
frequently among transplant recipients with no previous cardiac surgery,5,6 those
with a greater recipient-donor weight difference,6 and those who receive cyclospor-
ine (INN: ciclosporin) as part of the immunosuppressive protocol.7 The relationship
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between episodes of acute rejection and the genesis of
pericardial effusion is controversial. Ciliberto and associ-
ates5 and Valantine and colleagues8 have reported positive
associations between acute rejection and posttransplantation
effusion. However, a larger multivariate analysis by Haupt-
man and colleagues6 did not discern any relationship be-
tween these events.
Pericardial effusions tend to occur within the first 3
months after transplantation, and late development is un-
common.8 Their appearance may mandate surgical or cath-
eter drainage, but the effect of effusions on survival or other
outcome measures has not been well established. This study
was undertaken to identify characteristics of the donor, the
recipient, the operative procedure, and the early postopera-
tive course that predict the development of significant peri-
cardial effusion after orthotopic cardiac transplantation. The
study also examined the influence of pericardial effusions
on common posttransplantation outcome measures.
Methods
A retrospective review was conducted of 241 consecutive patients
undergoing orthotopic heart transplantation at St Paul Medical
Center in Dallas from September 1988 (when the program began)
to December 1999. Data collected included preoperative donor and
recipient demographic and clinical information, intraoperative
variables related to the conduct of the transplant operation, and
postoperative variables describing the hemodynamic course,
bleeding and transfusion requirements, and selected postoperative
complications. A complete list of variables collected and analyzed
is presented in Table 1.
TABLE 1. Variables included in the analysis
Preoperative variables
Donor age, gender, weight, height, ABO blood group, and cytomegalovirus status
Recipient age, gender, weight, height, ABO blood group, and cytomegalovirus status
Recipient United Network for Organ Sharing status at time of transplantation
Cause of recipient heart failure
No. of previous cardiac surgical procedures
Preoperative administration of heparin, warfarin, or aspirin
Preoperative serum creatinine, albumin, prothrombin time, partial thromboplastin time, and creatinine clearance
Pulmonary artery systolic, diastolic, and mean pressures; central venous pressure; pulmonary capillary wedge pressure; cardiac
output; cardiac index; and pulmonary vascular resistance at time of initial transplant evaluation
Pulmonary artery systolic, diastolic, and mean pressures; central venous pressure; pulmonary capillary wedge pressure; cardiac
output; cardiac index; and pulmonary vascular resistance at time closest to transplantation
Estimated recipient ejection fraction




Total donor ischemic time
Pulmonary artery systolic, diastolic and mean pressures; central venous pressure; pulmonary capillary wedge pressure; cardiac
output; cardiac index; and pulmonary vascular resistance first measured at time of operation
Intraoperative administration of aprotinin or aminocaproic acid
Intraoperative transfusion of packed red blood cells, fresh-frozen plasma, platelets, and cryoprecipitate
Surgical closure of the pericardium
Postoperative variables
Mediastinal chest tube drainage at 24 and 48 h
Postoperative transfusions of packed red blood cells, fresh-frozen plasma, platelets, and cryoprecipitate at 24 and 48 h
Postoperative use of epinephrine, isoproterenol (INN isoprenaline), milrinone, or dobutamine
Duration of inotropic support
Duration mediastinal chest tube drainage
Need for surgical re-exploration
No. of episodes of treated rejection within 3 mo of transplantation
Need for postoperative dialysis
Postoperative presence of edema
Pulmonary artery systolic, diastolic, and mean pressures; central venous pressure; pulmonary capillary wedge pressure; cardiac
output; cardiac index; and pulmonary vascular resistance measured at first postoperative right heart catheterization
Calculated variables
Weight difference between donor and recipient
Height difference between donor and recipient
Age difference between donor and recipient
Total transfusion volumes of packed red blood cells, fresh-frozen plasma, platelets, and cryoprecipitate during perioperative period
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Patients in whom postoperative pericardial effusions developed
were identified from echocardiograms performed within the first 3
months after transplantation. Effusions occurring later were not
considered in this study. Pericardial effusions when present were
graded according to the guidelines established by Martin and
coworkers.9 Small effusions were characterized as fluid collections
limited to the atrioventricular groove. Fluid collections that were
also distributed laterally, apically, or anteriorly were characterized
as moderate. Large fluid collections extended further posterome-
dially or circumferentially. On the basis of these findings, patients
were placed into two groups according to effusion size: those with
moderate or large effusions were considered to have significant
pericardial effusion, whereas those with small or undetectable
effusions were deemed to have no significant pericardial effusion.
Effusions that necessitated operative or catheter drainage proce-
dures were also noted.
Outcome data, including recipient survival, length of postop-
erative hospital stay, and rejection episodes, were also recorded for
all patients. The incidence of posttransplantation graft rejection
was assessed by review of all surveillance biopsies done for each
patient within the first 3 months after transplantation. Rejection
episodes were recorded if biopsy specimens demonstrated histo-
logic changes of grade 2 or higher according to the International
Society for Heart & Lung Transplantation guidelines10 and pa-
tients received treatment for rejection.
Statistical Analysis
Data were analyzed with commercially-available software (SAS
Institute, Inc, Cary, NC). A univariate analysis of all variables
listed in Table 1 was performed initially to assess for differences
between groups with and without significant pericardial effusion.
A 2 analysis was used for discrete variables, with P  .05
according to 2-tailed Fisher exact test used to select factors with
potential significance. For continuous variables, the Student t test
with the Welch approximation for unequal variances was used to
compare the two groups. Group differences were also considered
potentially significant at P  .05.
To account for a lack of independence among the variables,
additional testing was used. Variables with the potential for sig-
nificant difference between groups according to univariate analysis
were entered as candidate variables in a mulitvariate stepwise
logistic regression analysis. For each element remaining in the
multivariate model, a parameter estimate was calculated from
which a P value, odds ratio (OR), and 95% confidence interval
(CI) for the variable were derived.
To examine patient survival and freedom from rejection, esti-
mates based on the Kaplan-Meier method were created and com-
pared statistically with a log-rank test. Data are expressed as
mean  SD except in the case of survival data, which are reported
as mean  SEM.
Results
Between September 1988 and December 1999, a total of
241 patients underwent orthotopic heart transplantation.
Two hundred three patients had documented echocardio-
grams within the first 3 postoperative months, and these
patients form the study population. Forty-two patients had
significant pericardial effusion develop (13 large and 29
moderate effusions) according to the criteria described pre-
viously, and 19 of these patients required drainage. When
drainage was required, it was achieved by placement of a
subxiphoid pericardiostomy tube. In 2 cases the effusion
recurred, ultimately necessitating a pericardial window
through a limited thoracotomy. None of the patients under-
went prophylactic drainage of the pericardium into the
pleural space at the time of the initial operation.
Variables found to correlate with significant pericardial
effusion according to the univariate analysis are listed in
Table 2. Patients with significant pericardial effusion were
less likely to have had previous cardiac surgery and more
likely to be undergoing transplantation for idiopathic dilated
cardiomyopathy, to be younger, to be lighter, and to have
higher central venous pressure at time of transplant evalu-
ation. The use of hearts from female donors was associated
with significant effusion, as was intraoperative administra-
tion of the antifibrinolytic agent aminocaproic acid (Ami-
car). Patients with significant pericardial effusion were
found to have a lower incidence of postoperative pedal
edema.
Of the candidate variables found by univariate analysis,
three emerged as possible predictors of significant pericar-
dial effusion according to the multivariate logistic regres-
sion analysis (Table 3). Previous cardiac surgery was the
greatest deterrent to the development of pericardial effusion
(OR 0.13, 95% CI 0.05-0.36, P  .0002). The use of
aminocaproic acid increased the relative risk of pericardial
effusion nearly 6-fold. A greater recipient weight at the time
TABLE 2. Variables found to differ significantly between
patients with and without pericardial effusion after ortho-










Recipient age (y) 54.3 0.8 49.2 1.9 .01
Preoperative central venous
pressure (mm Hg)
15.5 0.6 19.7 1.8 .04
Recipient diagnosis of idiopathic
dilated cardiomyopathy
24% 50% .001
Previous cardiac surgery 54% 12% .001
Female donor heart 30% 52% .01




Postoperative pedal edema 55% 32% .01
Data are presented as mean  SEM for continuous variables and as
percentages of patients for discrete variables. Comparisons are by Student
t test for continuous variables and by Fisher exact test for discrete
variables.
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of transplantation emerged as slightly protective against the
development of pericardial effusion.
No association was found between rejection and the
development of pericardial effusions. Forty-five patients
required treatment for acute graft rejection within the first 3
months: 11 (26%) of 42 patients with pericardial effusions
and 34 (21%) of 161 patients without pericardial effusions
(P  .48). The 5-year freedoms from rejection of patients
with and without pericardial effusions were 73%  7% and
77% 3%, respectively (P .66). No correlation was seen
between the development of significant effusions and either
the duration or quantity of mediastinal chest tube drainage
or the quantity of blood and blood products administered in
the first 48 hours after transplantation.
The development of a postoperative pericardial effusion
did not appear to be related to any common outcome mea-
sures in this population. Actuarial survival calculated by the
Kaplan-Meier method was not different between transplant
recipients with and without significant postoperative effu-
sions. The 5-year survivals of patients with and without
pericardial effusions were 92%  4% and 83%  3%,
respectively (P  .15). Postoperative hospital stays were
19  3 days and 18  1 days among patients with and
without pericardial effusions, respectively (P  .66).
Discussion
Depending on the definition, postoperative pericardial effu-
sions may be found in as many as 70% of patients under-
going cardiac surgery. Most of these effusions are small and
asymptomatic, and they generally resolve within 2 weeks of
surgery, but some persist for several months and may even
rarely cause tamponade.11 The incidence of pericardial ef-
fusions among patients undergoing orthotopic cardiac trans-
plantation is similar to that associated with other open
cardiac procedures. Again, definitions of significant effu-
sions vary, but in this series of 203 patients, significant
(moderate and large) pericardial effusions occurred in 21%,
an incidence similar to the reports of others.12 Although no
patients with significant effusions had tamponade develop,
nearly half of these patients (n  19/42) did undergo a
drainage procedure.
According to univariate analysis, recipients with dilated
cardiomyopathy, no previous cardiac surgery, and younger
age were more likely to have significant pericardial effu-
sions develop. Other groups have reported associations with
dilated cardiomyopathy12 and the absence of previous car-
diac surgery.5,6 These variables are related, because patients
receiving transplants for dilated cardiomyopathy are signif-
icantly younger and significantly less likely to have under-
gone previous cardiac surgical procedures. It is therefore not
surprising that only one of these variables (the absence of
previous cardiac surgery) emerged as an independent pre-
dictor of pericardial effusions in the multivariate analysis.
Although previous studies have suggested that the devel-
opment of acute rejection may contribute to the develop-
ment of significant pericardial effusions,5,8 no such associ-
ation was identified in this study. However the incidence of
early acute rejection in this cohort was relatively low (45 of
203 patients), which may have influenced our ability to
detect an association. The use of cyclosporine, cited by
others as a possible cause of pericardial effusions,7 could
not be analyzed because all transplant recipients in this
study were treated with this drug after transplantation.
A statistical association between recipient weight and the
development of pericardial effusions was found, with
heavier recipients slightly protected from this complication.
This association was found only for absolute recipient
weight and not for the donor-recipient weight difference
(P  .17 by univariate analysis), as has been reported by
others.6 The reason for this finding was not determined by
this study, but one might speculate that a larger recipient
would have a greater pericardial surface over which post-
operative pericardial fluid could be distributed or absorbed.
This would be difficult to ascertain, because cardiac dimen-
sions are typically grossly enlarged before transplantation,
and body weight may not be a precise surrogate for heart
size in patients with heart failure. Direct measurements of
donor and recipient heart sizes with quantitative imaging
may provide more meaningful comparative data.
Use of the antifibrinolytic agent aminocaproic acid (ad-
ministered intravenously in a dose of 10 g after hepariniza-
tion plus 5 g added to the cardiopulmonary bypass circuit)
was found to be associated with a dramatically increased
incidence of postoperative pericardial effusion, a finding not
previously reported. Agents such as aminocaproic acid and
aprotinin are used in the perioperative setting to reduce
postoperative bleeding.13,14 They are used more frequently
for patients who have had previous cardiac surgery, because
of the increased risk for bleeding in this group. However,
aminocaproic acid use was identified as a predictor of
pericardial effusions independent of reoperative status ac-
cording to the multivariate analysis, whereas no association
with aprotinin was observed. It is possible that the admin-
istration of an antifibrinolytic agent may contribute to re-
tention of clots within the pericardial sac. Subsequent clot
TABLE 3. Variables found to differ significantly between
patients with and without pericardial effusion after ortho-
topic heart transplantation, as determined by multivariate
logistic regression analysis
Variable OR 95% CI P value




Greater recipient weight 0.96 0.94-0.99 .0048
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lysis could encourage fluid inspissation, leading to an effusion.
However, it is noteworthy that the amount of mediastinal chest
drainage, duration of chest tube drainage, and the quantities of
blood products administered after transplantation were not
found to correlate with the development of pericardial effu-
sions. Also, the amount of mediastinal blood loss within the
first 48 postoperative hours was not different between patients
who received aminocaproic acid (1500  210 mL), aprotinin
(1673  186 mL), or neither (1483  100 mL).
This study has several limitations. It is retrospective in
design, and some data could not be obtained because of the
unavailability of records. Harvesting and implantation pro-
cedures were performed by several surgeons, and there may
have been subtle differences in operative technique that
could have influenced outcomes. In addition, there may
have been evolutionary changes in management protocols
or patient selection criteria during the 12-year study interval
that were not accounted for in this analysis. Antifibrinolytic
agents were administered according to the judgment of the
surgeon, anesthesiologist, and perfusionist at the time of
surgery rather than according to a predetermined protocol.
Finally, echocardiographic data may be somewhat subjec-
tive, and other definitions of pericardial effusions may be
more appropriate. We applied the echocardiographic criteria
defined by Martin and coworkers,9 because these guidelines
have been used in other reports examining pericardial effu-
sions in transplantation. When the analysis was repeated
with a significant pericardial effusion defined as one neces-
sitating surgical or catheter drainage (n  19), multivariate
analysis identified a diagnosis of dilated cardiomyopathy
(OR 8.03, 95% CI 2.61-24.66, P  .0001) and use of
aminocaproic acid (OR 5.44, 95% CI 1.76-16.87, P 
.0019) as significant predictors.
As with any retrospective study, there are limitations to the
statistical analysis and its interpretation. The number of pa-
tients in whom pericardial effusions developed totaled only 42,
and the number of predictors initially screened by univariate
techniques exceeded this value. Even the entry of 8 candidate
variables into the multivariate analysis may risk overfitting
with this number of outcomes.15 Continuous variables such as
recipient weight are modeled with the assumption that the risk
for the outcome is linear across the range of weights included.
This analysis does not account for the possibility that risk is not
linear (as might be seen if the risk for pericardial effusion
increases for very low weights and then levels off at higher
weights). Finally, the meaning of the significant effects ob-
served in this or any other retrospective study must be inter-
preted with caution. The variables identified as predictors may
represent surrogates for other conditions that more directly
affect the outcome.
To our knowledge, this is the largest study evaluating
factors contributing to the development of significant peri-
cardial effusions after orthotopic cardiac transplantation.
Previous cardiac procedures and greater recipient weight
appear protective, whereas the use of aminocaproic acid
appears to increase the risk of this complication. An asso-
ciation with acute rejection was not identified. On the basis
of the currently identified factors, the development of peri-
cardial effusions may be difficult to prevent, although
avoiding the use of aminocaproic acid should be considered.
The development of pericardial effusion does not appear to
prolong hospital stay or affect survival. However, the pres-
ence of one or more risk factors in the patient undergoing
orthotopic heart transplantation should lead to heightened
awareness of this potential complication.
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